Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Comprehensive Stroke Center Designations Could Decrease “Weekend Effect”

By HospiMedica International staff writers
Posted on 19 Sep 2011
A new study claims that stroke patients admitted on the weekend have higher death rates than those admitted on weekdays at many hospitals, but not at comprehensive stroke centers (CSCs).

Researchers at the at the University of Medicine and Dentistry New Jersey (UMDNJ; New Brunswick, USA) examined records of 134,441 stroke patients discharged from 88 private acute care hospitals in the state of New Jersey (USA) between 1997 and 2007. More...
Among these, 23.4% were admitted to one of 12 CSCs, 51.5% to one of 43 primary stroke centers, and 25.1% to one of 33 non-stroke centers. The researchers determined out-of-hospital mortality rates up to one year after admission.

The results showed that 28% of all stroke patients were admitted on the weekend, and that these patients had a significantly higher death rate (17.2%) within 90 days, when compared to patients admitted on a weekday (16.5%). After adjusting for patient demographics and coexisting conditions, the weekend effect represented a 5% difference in overall death rates. The researchers also found that although patients admitted after 2006 were 10 times more likely to receive intravenous (IV) thrombolysis treatment using analogs of tissue plasminogen activator (tPA), the "weekend effect" was still evident for stroke patients admitted to primary stroke centers or non-stroke centers. The study was published in the September 2001 issue of Stroke.

“The 'weekend effect' suggests patients admitted or treated during weekend hours will receive different care, have worse outcomes, which could account for several thousand US deaths,” said lead author James McKinney, MD, an assistant professor of neurology at UMDNJ. “Prior studies of the weekend effect have looked at in-hospital death rates and death rates right after discharge, but we wanted to look at longer outcomes after admission. We also wanted to determine if New Jersey's unique stroke center designations impacted patient treatment and outcomes.”

TPA is a serine protease found on the endothelial cells that line the blood vessels, and is also manufactured using recombinant biotechnology techniques. As an enzyme, it catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. Because it works on the clotting system, tPA is used in clinical medicine to treat only embolic or thrombotic stroke. Use is contraindicated in hemorrhagic stroke and head trauma.

Related Links:

University of Medicine and Dentistry New Jersey






New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Resorbable Bovine Collagen Membrane
GenDerm
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.